Impact of Minimal Residual Disease, Detected by Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia

Overview

Journal Leuk Res Treatment

Date 2014 Apr 30

PMID 24778882

Citations 38

Authors

Merav Bar

Brent L Wood

Jerald P Radich

Kristine C Doney

Ann E Woolfrey

Colleen Delaney

Frederick R Appelbaum

Ted A Gooley

Affiliations

Soon will be listed here.

Abstract

In this retrospective study, we evaluated the impact of pre- and posttransplant minimal residual disease (MRD) detected by multiparametric flow cytometry (MFC) on outcome in 160 patients with ALL who underwent myeloablative allogeneic hematopoietic cell transplantation (HCT). MRD was defined as detection of abnormal B or T cells by MFC with no evidence of leukemia by morphology (<5% blasts in marrow) and no evidence of extramedullary disease. Among 153 patients who had pre-HCT flow data within 50 days before transplant, MRD pre-HCT increased the risk of relapse (hazard ratio (HR) = 3.64; 95% confidence interval (CI), 1.87-7.09; P = .0001) and mortality (HR = 2.39; 95% CI, 1.46-3.90, P = .0005). Three-year estimates of relapse were 17% and 38% and estimated 3-year OS was 68% and 40% for patients without and with MRD pre-HCT, respectively. 144 patients had at least one flow value post-HCT, and the risk of relapse among those with MRD was higher than that among those without MRD (HR = 7.47; 95% CI, 3.30-16.92, P < .0001). The risk of mortality was also increased (HR = 3.00; 95% CI, 1.44-6.28, P = .004). These data suggest that pre- or post-HCT MRD, as detected by MFC, is associated with an increased risk of relapse and death after myeloablative HCT for ALL.

Citing Articles

Effects of isolated central nervous system involvement evaluated by multiparameter flow cytometry prior to allografting on outcomes of patients with acute lymphoblastic leukemia.

Ma L, Xu L, Wang Y, Zhang X, Chen H, Chen Y Front Oncol. 2023; 13:1166990.

PMID: 37251948 PMC: 10209422. DOI: 10.3389/fonc.2023.1166990.

Immunophenotypic measurable residual disease monitoring in adult acute lymphoblastic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.

Tecchio C, Russignan A, Krampera M Front Oncol. 2023; 13:1047554.

PMID: 36910638 PMC: 9992536. DOI: 10.3389/fonc.2023.1047554.

Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 Years.

Webster J, Reed M, Tsai H, Ambinder A, Jain T, DeZern A Transplant Cell Ther. 2023; 29(3):182.e1-182.e8.

PMID: 36587740 PMC: 9992271. DOI: 10.1016/j.jtct.2022.12.018.

Peripheral blood marker of residual acute leukemia after hematopoietic cell transplantation using multi-plex digital droplet PCR.

Stanojevic M, Grant M, Vesely S, Knoblach S, Kanakry C, Nazarian J Front Immunol. 2022; 13:999298.

PMID: 36248870 PMC: 9556966. DOI: 10.3389/fimmu.2022.999298.

Therapeutic Role of Carotenoids in Blood Cancer: Mechanistic Insights and Therapeutic Potential.

Hussain Y, Abdullah , Alsharif K, Aschner M, Theyab A, Khan F Nutrients. 2022; 14(9).

PMID: 35565917 PMC: 9104383. DOI: 10.3390/nu14091949.

References

Wood B . Ten-color immunophenotyping of hematopoietic cells. Curr Protoc Cytom. 2008; Chapter 6:Unit6.21. DOI: 10.1002/0471142956.cy0621s33. View

Wood B . 9-color and 10-color flow cytometry in the clinical laboratory. Arch Pathol Lab Med. 2006; 130(5):680-90. DOI: 10.5858/2006-130-680-CACFCI. View

Knechtli C, Goulden N, Hancock J, Grandage V, Harris E, Garland R . Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood. 1998; 92(11):4072-9. View

Kerst G, Kreyenberg H, Roth C, Well C, Dietz K, Coustan-Smith E . Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Br J Haematol. 2005; 128(6):774-82. DOI: 10.1111/j.1365-2141.2005.05401.x. View

Uzunel M, Jaksch M, Mattsson J, Ringden O . Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia. Br J Haematol. 2003; 122(5):788-94. DOI: 10.1046/j.1365-2141.2003.04495.x. View

Gaipa G, Cazzaniga G, Valsecchi M, Panzer-Grumayer R, Buldini B, Silvestri D . Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia. Haematologica. 2012; 97(10):1582-93. PMC: 3487561. DOI: 10.3324/haematol.2011.060426. View

Stirewalt D, Guthrie K, Beppu L, Bryant E, Doney K, Gooley T . Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation. Biol Blood Marrow Transplant. 2003; 9(3):206-12. DOI: 10.1053/bbmt.2003.50025. View

Sanchez J, Serrano J, Gomez P, Martinez F, Martin C, Madero L . Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation. Br J Haematol. 2002; 116(3):686-94. DOI: 10.1111/j.1365-2141.2002.3311a.x. View

van Dongen J, Seriu T, Panzer-Grumayer E, Biondi A, Corral L, Stolz F . Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998; 352(9142):1731-8. DOI: 10.1016/S0140-6736(98)04058-6. View

10.

Bader P, Kreyenberg H, Henze G, Eckert C, Reising M, Willasch A . Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol. 2008; 27(3):377-84. DOI: 10.1200/JCO.2008.17.6065. View

11.

Bruggemann M, Raff T, Kneba M . Has MRD monitoring superseded other prognostic factors in adult ALL?. Blood. 2012; 120(23):4470-81. DOI: 10.1182/blood-2012-06-379040. View

12.

Holowiecki J, Krawczyk-Kulis M, Giebel S, Jagoda K, Stella-Holowiecka B, Piatkowska-Jakubas B . Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study. Br J Haematol. 2008; 142(2):227-37. DOI: 10.1111/j.1365-2141.2008.07185.x. View

13.

Zhao X, Liu Y, Zhu H, Xu L, Liu D, Liu K . Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2011; 91(2):183-92. DOI: 10.1007/s00277-011-1285-1. View

14.

Sramkova L, Muzikova K, Fronkova E, Krejci O, Sedlacek P, Formankova R . Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2006; 48(1):93-100. DOI: 10.1002/pbc.20794. View

15.

Schrappe M . Minimal residual disease: optimal methods, timing, and clinical relevance for an individual patient. Hematology Am Soc Hematol Educ Program. 2012; 2012:137-42. DOI: 10.1182/asheducation-2012.1.137. View

16.

Coustan-Smith E, Sancho J, Hancock M, Boyett J, Behm F, Raimondi S . Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 2000; 96(8):2691-6. View

17.

Terwey T, Le Duc T, Hemmati P, le Coutre P, Nagy M, Martus P . NIH-defined graft-versus-host disease and evidence for a potent graft-versus-leukemia effect in patients with acute lymphoblastic leukemia. Ann Oncol. 2012; 24(5):1363-70. DOI: 10.1093/annonc/mds615. View

18.

Campana D . Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care?. Curr Hematol Malig Rep. 2012; 7(2):170-7. DOI: 10.1007/s11899-012-0115-4. View

19.

Borowitz M, Devidas M, Hunger S, Bowman W, Carroll A, Carroll W . Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood. 2008; 111(12):5477-85. PMC: 2424148. DOI: 10.1182/blood-2008-01-132837. View

20.

Malec M, van der Velden V, Bjorklund E, Wijkhuijs J, Soderhall S, Mazur J . Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping. Leukemia. 2004; 18(10):1630-6. DOI: 10.1038/sj.leu.2403444. View